+

TWI365191B - Vaccine - Google Patents

Vaccine

Info

Publication number
TWI365191B
TWI365191B TW094126452A TW94126452A TWI365191B TW I365191 B TWI365191 B TW I365191B TW 094126452 A TW094126452 A TW 094126452A TW 94126452 A TW94126452 A TW 94126452A TW I365191 B TWI365191 B TW I365191B
Authority
TW
Taiwan
Prior art keywords
vaccine
Prior art date
Application number
TW094126452A
Other languages
English (en)
Other versions
TW200621806A (en
Inventor
Helge Abrecht
Martine Delchambre
Martine Marchand
Nathalie Louise Mathy
Philippe Jean Gervais Ghislain Permanne
Gerald Hermann Voss
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of TW200621806A publication Critical patent/TW200621806A/zh
Application granted granted Critical
Publication of TWI365191B publication Critical patent/TWI365191B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW094126452A 2004-08-05 2005-08-03 Vaccine TWI365191B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0417494.2A GB0417494D0 (en) 2004-08-05 2004-08-05 Vaccine

Publications (2)

Publication Number Publication Date
TW200621806A TW200621806A (en) 2006-07-01
TWI365191B true TWI365191B (en) 2012-06-01

Family

ID=32982606

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094126452A TWI365191B (en) 2004-08-05 2005-08-03 Vaccine

Country Status (32)

Country Link
US (2) US7612173B2 (zh)
EP (3) EP1773999B1 (zh)
JP (3) JP2008507987A (zh)
KR (1) KR101501495B1 (zh)
CN (2) CN102633866B (zh)
AR (2) AR050102A1 (zh)
AT (1) ATE443769T1 (zh)
AU (1) AU2005268856B2 (zh)
BR (1) BRPI0514108A (zh)
CA (1) CA2575898C (zh)
CY (1) CY1109667T1 (zh)
DE (1) DE602005016810D1 (zh)
DK (1) DK1773999T3 (zh)
ES (3) ES2445453T3 (zh)
GB (1) GB0417494D0 (zh)
HK (1) HK1108168A1 (zh)
HR (1) HRP20090678T1 (zh)
IL (2) IL180947A0 (zh)
MA (1) MA28983B1 (zh)
MX (1) MX2007001515A (zh)
MY (1) MY145614A (zh)
NO (1) NO20070988L (zh)
NZ (1) NZ552976A (zh)
PE (1) PE20060577A1 (zh)
PL (1) PL1773999T3 (zh)
PT (1) PT1773999E (zh)
RU (1) RU2441878C2 (zh)
SG (1) SG155206A1 (zh)
SI (1) SI1773999T1 (zh)
TW (1) TWI365191B (zh)
WO (1) WO2006013106A2 (zh)
ZA (1) ZA200700771B (zh)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
JP4838936B2 (ja) * 1998-10-23 2011-12-14 イデア アクチェンゲゼルシャフト 装荷量を改善しおよび脱／会合速度を制御可能とするための、巨大分子と複合凝集体との会合体を開発し、テストし、かつ利用する方法
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
CA2584475A1 (en) * 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
BRPI0608798A2 (pt) * 2005-05-12 2011-03-15 Glaxo Group Ltd vetor de adenovìrus, composição imunogênica, uso de um vetor de adenovìrus, método para preparar um vetor, uso de um vetor de vìrus e um carreador ou adjuvante farmaceuticamente aceitável, e, proteìna de fusão
EP1885186B1 (en) 2005-06-01 2015-09-02 California Institute Of Technology Method of targeted gene delivery using viral vectors
CA2651764A1 (en) * 2006-05-09 2007-11-22 Gerald V. Quinnan Hiv-1 immunogenic compositions
EP2520168B1 (en) 2006-07-21 2014-03-19 California Institute of Technology Targeted gene delivery for dendritic cell vaccination
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
EP2998316B1 (en) * 2007-03-02 2019-06-12 GlaxoSmithKline Biologicals S.A. Novel method and compositions
US20110244496A1 (en) * 2007-03-06 2011-10-06 Rutgers, The State University Hiv reverse transcriptase compositions and methods
AU2008230849A1 (en) * 2007-03-26 2008-10-02 International Aids Vaccine Initiative Method of eliciting immune response with a modified MVA viral HIV-1 vector
SI2148697T1 (sl) 2007-05-24 2013-01-31 Glaxosmithkline Biologicals S.A. Liofilizirani sestavek, ki vsebuje CpG in WT-1
BRPI0821555A2 (pt) * 2007-12-21 2015-06-16 Glaxosmithline Biolog S A Componente para uma vaciana de hiv ou massa, componente ou massa líquida liofilizados, composição farmacêutica ou vacina, usos do componente ou massa final ou da composição farmacêutica e de um antioxidante com pelo menos um grupo funcional tiol e métodos de tratamento e de reconstituição de um componente liofilizado, e kit
RU2539765C2 (ru) * 2008-07-16 2015-01-27 Бейлор Рисёч Инститьют ВИЧ ВАКЦИНА, ОСНОВАННАЯ НА НАПРАВЛЕННОСТИ МАКСИМИЗИРОВАННЫХ Gag И Nef НА ДЕНДРИТНЫЕ КЛЕТКИ
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010029562A1 (en) 2008-09-09 2010-03-18 Mukesh Harilal Shukla Bioactive composition for the treatment of the hiv/aids, method for manufacturing and using the same
NZ597804A (en) 2009-07-24 2013-10-25 Immune Design Corp Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
CN103221065A (zh) 2010-03-26 2013-07-24 葛兰素史密斯克莱生物公司 Hiv疫苗
RU2583289C2 (ru) * 2010-05-14 2016-05-10 Бакстер Интернэшнл Инк. Химерные гены ospa, белки и способы их применения
EA201390452A1 (ru) 2010-09-27 2013-11-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина
JP2012120506A (ja) * 2010-12-10 2012-06-28 Tosoh Corp Ａｍｖ逆転写酵素遺伝子、該遺伝子によりコードされるａｍｖ逆転写酵素及び該遺伝子を用いるａｍｖ逆転写酵素の製造方法
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
JP2013146235A (ja) * 2012-01-20 2013-08-01 Tosoh Corp トリ骨髄芽細胞腫ウイルス逆転写酵素の製造方法
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
NZ700340A (en) 2012-03-30 2017-02-24 Immune Design Corp Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
CN106714800B (zh) 2014-07-11 2021-09-03 吉利德科学公司 用于治疗hiv的toll样受体调节剂
KR102014518B1 (ko) 2017-01-05 2019-08-26 서울대학교산학협력단 HIV 1의 p24 단백질을 발현하는 벡터가 도입된 재조합 마이코박테리움 스메그마티스 균주 및 이를 포함하는 백신
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
WO2021094984A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
JP2023520370A (ja) 2020-03-27 2023-05-17 スヴェンスカ ヴァクチンファブリケン プロダクション アーベー コロナウイルスの治療および予防のための組成物および方法
MX2023008272A (es) 2021-01-14 2023-07-19 Gilead Sciences Inc Vacunas contra el virus de la inmunodeficiencia humana (vih) y metodos de uso.
US20230295244A1 (en) 2021-09-29 2023-09-21 Svenska Vaccinfabriken Produktion Ab Compositions and methods for treating and preventing coronaviruses

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DE3300234A1 (de) 1983-01-05 1984-07-05 Display-Design GmbH für moderne Verkaufsförderungsmittel und Raumaussstattung, 6233 Kelkheim Etagenturm zur warenausstellung
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
DK643188A (da) * 1987-11-24 1989-05-25 Smithkline Biolog Ekspression af hiv-proteiner i e.coli og s.cerevisiae
US5221610A (en) 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
KR0172970B1 (ko) 1992-06-17 1999-02-01 김영길 Aids백신에 유용한 키메릭 단백 및 그의 제조방법
ATE156710T1 (de) 1992-06-25 1997-08-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
DE69434151D1 (de) 1993-05-18 2004-12-30 Biomolecular Res Inst Ltd Therapeutische inhaltsstoffe
AU700485B2 (en) 1993-11-17 1999-01-07 Om Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE328890T1 (de) 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
EP2050465B1 (en) 1997-08-29 2014-06-11 Antigenics Inc. Compositions comprising the adjuvant QS-21 and polysorbate or cyclodextrin as excipient
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
WO2000007631A1 (en) 1998-08-04 2000-02-17 The Henry M. Jackson Foundation Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
AU782193B2 (en) 1999-12-17 2005-07-07 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef
MXPA02006379A (es) * 1999-12-23 2004-06-21 Medical Res Council Mejoriasen o relacionadas con la respuesta inmune a vih.
US20020155127A1 (en) * 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
WO2002022080A2 (en) 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
CU23235A1 (es) * 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
IL160809A0 (en) * 2001-09-20 2004-08-31 Glaxo Group Ltd HIV-gag CODON-OPTIMISED DNA VACCINES
US7247472B2 (en) 2001-11-21 2007-07-24 The Trustees Of The University Of Pennsylavania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
AU2002360429A1 (en) 2001-11-26 2003-06-10 Avigen, Inc. Methods for producing stocks of recombinant aav virions
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
AU2003216852B2 (en) * 2002-03-19 2008-09-11 Glaxo Group Limited Imidazoquinolineamines as adjuvants in HIV DNA vaccination
PT1511768E (pt) * 2002-06-11 2007-07-16 Glaxo Group Ltd Composições imunogénicas
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US7501503B2 (en) * 2002-12-31 2009-03-10 Mcgill University Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase
US20050175627A1 (en) 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines
EP1682666B1 (en) 2003-09-24 2008-12-31 Oxxon Therapeutics Limited HIV Pharmaceutical vaccines

Also Published As

Publication number Publication date
EP2130921B1 (en) 2013-11-20
AU2005268856A1 (en) 2006-02-09
GB0417494D0 (en) 2004-09-08
CA2575898C (en) 2015-09-29
CA2575898A1 (en) 2006-02-09
HK1108168A1 (en) 2008-05-02
RU2007104088A (ru) 2008-09-10
BRPI0514108A (pt) 2008-05-27
PL1773999T3 (pl) 2010-02-26
MA28983B1 (fr) 2007-11-01
PT1773999E (pt) 2009-12-16
IL207575A0 (en) 2011-07-31
CN101035897A (zh) 2007-09-12
DK1773999T3 (da) 2010-01-18
EP2130921A2 (en) 2009-12-09
EP2280073A2 (en) 2011-02-02
SI1773999T1 (sl) 2010-01-29
JP5629647B2 (ja) 2014-11-26
US20070243203A1 (en) 2007-10-18
MX2007001515A (es) 2007-09-07
EP1773999B1 (en) 2009-09-23
WO2006013106A2 (en) 2006-02-09
KR101501495B1 (ko) 2015-03-11
JP2014239687A (ja) 2014-12-25
AR050102A1 (es) 2006-09-27
ES2334044T3 (es) 2010-03-04
EP1773999A2 (en) 2007-04-18
JP6007212B2 (ja) 2016-10-12
TW200621806A (en) 2006-07-01
JP2011234722A (ja) 2011-11-24
CN102633866B (zh) 2015-04-15
EP2280073A3 (en) 2011-06-29
CY1109667T1 (el) 2014-08-13
CN102633866A (zh) 2012-08-15
MY145614A (en) 2012-03-15
HRP20090678T1 (hr) 2010-01-31
RU2441878C2 (ru) 2012-02-10
DE602005016810D1 (de) 2009-11-05
NZ552976A (en) 2010-01-29
KR20070041765A (ko) 2007-04-19
ZA200700771B (en) 2009-04-29
ES2486669T3 (es) 2014-08-19
ES2445453T3 (es) 2014-03-03
PE20060577A1 (es) 2006-08-07
CN101035897B (zh) 2012-02-01
EP2130921A3 (en) 2010-03-03
US20100184836A1 (en) 2010-07-22
EP2280073B1 (en) 2014-06-11
NO20070988L (no) 2007-05-04
SG155206A1 (en) 2009-09-30
AR080216A2 (es) 2012-03-21
ATE443769T1 (de) 2009-10-15
AU2005268856B2 (en) 2012-05-24
IL180947A0 (en) 2007-07-04
JP2008507987A (ja) 2008-03-21
WO2006013106A3 (en) 2006-08-17
US7612173B2 (en) 2009-11-03

Similar Documents

Publication Publication Date Title
TWI365191B (en) Vaccine
IL178890A0 (en) Vaccines
GB0922611D0 (en) Improved vaccines
IL192084A0 (en) Vaccine
GB0504436D0 (en) Vaccine
GB0409940D0 (en) Vaccine
GB0420634D0 (en) Vaccines
GB0411150D0 (en) Vaccine
ZA200709207B (en) Vaccine
GB0413510D0 (en) Vaccine
GB0515135D0 (en) Vaccine
GB0810662D0 (en) Vaccine
GB0516944D0 (en) Vaccine
GB0428381D0 (en) Vaccine
GB0412407D0 (en) Vaccine
GB0406598D0 (en) Vaccine
GB0419918D0 (en) Vaccine
IL179254A0 (en) An anti-theileriosis vaccine
GB0425339D0 (en) Vaccine
GB0413371D0 (en) Vaccine
GB0412547D0 (en) Vaccine
GB0416833D0 (en) Vaccine
GB0416398D0 (en) Vaccine
GB0413154D0 (en) Vaccine
GB0413513D0 (en) Vaccine

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载